3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
548
pembrolizumab
384
Radiotherapy
363
Bevacizumab
360
Carboplatin
351
Rituximab
315
Cisplatin
300
Gemcitabine
297
Paclitaxel
288
Dexamethasone
272
Docetaxel
271
fludarabine phosphate
241
Doxorubicin
231
Nivolumab
220
Etoposide
209
Cytarabine
203
Lenalidomide
201
fludarabine
191
Oxaliplatin
191
Fluorouracil
190
Melphalan
189
Filgrastim
188
Capecitabine
175
Calcium Dobesilate
172
Radiosurgery
167
Erlotinib Hydrochloride
167
Methotrexate
163
Bortezomib
162
Granulocyte Colony-Stimulating Factor
154
Whole-Body Irradiation
144
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Has results
×
flt3 ligand protein
×
Clear all
NCT04491084
2024-02-28
FLT3
Albert Einstein College of Medicine
Phase 1/2
Terminated
5 enrolled
8 charts